Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240630 · ClinicalTrials.gov registry record · Phase 3
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 646
- Enrollment target
NCT00240630 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 646 participants.
The verdict
NCT00240630, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 646 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
Interventions
- DRUG placebo
- DRUG sumatriptan succinate/naproxen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240630
The ClinicalTrials.gov registry entry for NCT00240630 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00240630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240630 about?
NCT00240630 is a clinical study titled "Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks". The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
What is the current status of trial NCT00240630?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 646 participants. The study started on 2005-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00240630?
The interventions under investigation include: placebo (DRUG), sumatriptan succinate/naproxen sodium (DRUG).
Who is sponsoring clinical trial NCT00240630?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.